Kiora Pharmaceuticals

Home
United States
Encinitas, CA
Kiora Pharmaceuticals

Clinical stage biotech company focusing on novel therapeutics for the treatment of retinal diseases Kiora Pharmaceuticals, Inc.

(Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

06/04/2025

As researchers continue to discover new gene variants linked to inherited blindness, the case for mutation-agnostic therapies grows stronger.

A recent study from the University of Oklahoma uncovered 20 newly identified gene variants in retinal disease – adding to an already complex genetic landscape.

While gene therapies remain a potentially powerful approach, they are often specific to a particular mutation. That’s why we’re developing KIO-301: a mutation-agnostic small molecule designed to restore light perception regardless of the underlying genetics.

It’s not about replacing gene therapies – but expanding options for patients. Mutation-agnostic approaches like 301 can work alone or alongside gene therapy, creating a more inclusive future for patients.

🔗 Read the study: https://eyewire.news/news/university-of-oklahoma-study-identifies-20-novel-variants-for-inherited-retinal-diseases?c4src=article:infinite-scroll
🔬 Learn about KIO-301: https://bit.ly/Kiora_Home

05/27/2025

Our passion is to develop innovations in biology to transform patients’ everyday lives. It’s stories like this that remind us how those with inherited retinal diseases are affected even in the little moments, like playing with their dog. This Kiora Pharmaceuticals clinical trial participant noticed an inspiring improvement in her vision—she was able to see her dog more clearly than ever before!

KIO-301 offers a new possibility for those who may not have treatment options.

Learn more about KIO-301 and its potential impact on patients’ lives: https://bit.ly/KioraHome.

05/16/2025

📢 Advancing KIO-104 for Retinal Macular Edema

Kiora has received clearance to begin KLARITY, a Phase 2 clinical trial evaluating KIO-104, a DHODH inhibitor, for treating macular edema —a condition where inflammation plays a key role.
This follows a recent grant of a composition-of-matter patent, which strengthens the company’s IP protection. The patent specifically covers a distinct crystalline form of the drug that allows for optimized production, stability, and delivery—enhancing the potential of KIO-104.

Together, these milestones move KIO-104 closer to becoming a non-steroidal option for retinal inflammation.

🔗 Trial announcement:
https://ir.kiorapharma.com/news-events/news-releases/detail/227/kiora-receives-approval-to-initiate-klarity-a-phase-2-clinical-trial-of-kio-104-for-the-treatment-of-retinal-macular-edema

🔗 Patent news:
https://ir.kiorapharma.com/news-events/news-releases/detail/228/kiora-pharmaceuticals-secures-u-s-composition-of-matter-patent-expanding-protection-of-its-anti-inflammatory-compound-kio-104

05/05/2025

We’re excited that Romana Seda-Zehetner MSc MScTox, Director Preclinical Development at Kiora Pharmaceuticals, presented data from a preclinical study at ARVO 2025 demonstrating the potential of KIO-104 to treat proliferative vitreoretinopathy (PVR).

PVR, which has no approved therapies, is the leading complication following retinal detachment surgery. The condition results in scarring, which may lead to repeated retinal detachments as well as progressive and permanent vision loss. The poster presentation highlighted a novel anti-proliferative approach, demonstrating KIO-104 significantly reduced scar size and formation in an established model of PVR. By targeting T cell–mediated pathways, KIO-104 may offer a new therapeutic approach to reducing ﬁbrotic scarring and preventing recurrent retinal detachment.

Glad to participate in ARVO and share how KIO-104 is shaping the future of ophthalmic treatments. Stay tuned for updates from the Kiora team.

Learn more here:
https://ir.kiorapharma.com/news-events/news-releases/detail/232/kiora-pharmaceuticals-presents-in-vivo-preclinical-data-at-arvo-2025-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy

05/01/2025

🔬 Presenting at ARVO 2025: Advancing a Novel Approach to addressing PVR

We’re pleased to share that Kiora Pharmaceuticals will present preclinical data on KIO-104 for the treatment of proliferative vitreoretinopathy (PVR) at the upcoming ARVO 2025 Annual Meeting.

The abstract highlights a novel anti-inﬂammatory approach for PVR, a vision-threatening complication in the surgical repair of retinal detachments, which has no approved therapies. In preclinical models, KIO-104 demonstrated suppression of the scarring seen in PVR.

By targeting T cell–mediated pathways, KIO-104 may offer a new therapeutic approach to reducing ﬁbrotic scarring and preventing recurrent retinal detachment.

📅 ARVO - May 4, 2025
📍 Salt Lake City, UT

🔗 Read the announcement here: https://ir.kiorapharma.com/news-events/news-releases/detail/229/kiora-pharmaceuticals-to-present-preclinical-data-on-kio-104-for-the-treatment-of-proliferative-vitreoretinopathy-at-the-arvo-2025-annual-meeting

03/20/2025

Our mission is driven by a passion for innovation and hope—developing potential treatments to transform patients' everyday lives. Stories like this remind us of the profound impact inherited retinal diseases can have, even in the simplest moments, like playing with a beloved dog. One of our Kiora Pharmaceuticals clinical trial participants shared an inspiring milestone: for the ﬁrst time, she was able to see her dog more clearly than ever before!

KIO-301 offers a new possibility for those who may not have treatment options.

Learn more about KIO-301 and its potential impact on patients’ lives: https://bit.ly/KioraHome.

03/13/2025

A Kiora Pharmaceuticals clinical trial participant experienced an impactful development in his journey with vision loss. We’re excited to share that this patient reported signiﬁcant improvement in his vision, allowing him to enjoy hobbies like early morning bike rides.

This breakthrough underscores the transformative possibilities of KIO-301, our innovative drug designed to restore functional vision in those with inherited retinal diseases.

Learn more about KIO-301 and its potential impact on patients’ lives: https://bit.ly/KioraHome.

02/27/2025

Brian M Strem, PhD & Chief Executive Officer at Kiora Pharmaceuticals, discusses the promising approach of KIO-301, our small molecule that works to restore functional vision by making retinal ganglion cells light sensitive.

Listen to the full Global Genes podcast here to learn more about KIO-301 and its potential impact on patients’ lives: https://globalgenes.org/raredaily/restoring-vision-in-inherited-retinal-diseases/

02/20/2025

As we make exciting progress towards our Phase 2 KLARITY trial of KIO-104, we're proud to spotlight this non-steroidal drug designed to treat retinal inﬂammation.

Oral drugs that inhibit the DHODH enzymes have helped hundreds of thousands of people with autoimmune diseases including multiple sclerosis and rheumatoid arthritis. When delivered directly to the eye, KIO-104 has the potential to improve the quality of life for individuals impacted by retinal inﬂammation.

Learn more about KIO-104 and its potential impact on patients’ lives: https://bit.ly/KioraHome.

02/14/2025

With our recent news of KIO-301 advancing towards its Phase 2 trial, we’d like to share more about this groundbreaking approach to restoring vision loss. The upcoming ABACUS-2 trial will enroll 36 patients with ultra-low vision or no light perception, regardless of underlying genetic mutation. With no currently approved therapies for patients with retinitis pigmentosa, our KIO-301 study will be an important step toward offering a potential path forward.

KIO-301 is a molecular photoswitch, a new class of potential vision restoring treatments for retinal diseases being developed by Kiora. Our hope is to help restore vision in patients with inherited retinal diseases and/or age-related retinal degeneration.

Learn more about KIO-301 and its potential impact on patients’ lives: https://bit.ly/KioraHome.

Address

332 Encinitas Boulevard, Suite 102
Encinitas, CA
92024

Website

http://kiorapharma.com/

Alerts

Be the first to know and let us send you an email when Kiora Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Kiora Pharmaceuticals: